Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Glioma
IDH-mutant astrocytoma and oligodendroglioma, IDH inhibitors, and BRAF- and H3-altered tumours.
Live from ClinicalTrials.gov, fetched 2026-11-12 11:57 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
37%
222 trial titles name relapsed, refractory or recurrent disease
Led by industry
24%
141 trials with a company as lead sponsor
60 of the 600 glioma trials are Phase 3; 35 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of glioma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 183 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Adjuvant1L · Maintenance1L · Relapsed or refractory1p/19q1p/19q · Maintenance2L+ · Advanced or metastaticAdjuvantAdvanced or metastaticBRAFBRAF · Advanced or metastaticBRAF · Relapsed or refractoryH3 K27H3 K27 · Relapsed or refractoryIDHIDH · 1LIDH · 1L · Relapsed or refractoryIDH · Advanced or metastaticIDH · MaintenanceIDH · Relapsed or refractoryLocally advancedMaintenanceNeoadjuvant or perioperativeRelapsed or refractory
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Dabrafenib Cancer Research UK | BRAF | Small molecule | Ph2/Ph3 | NCT07440290 |
| Trametinib Cancer Research UK | BRAF | Small molecule | Ph2/Ph3 | NCT07440290 |
| Plixorafenib Fore Biotherapeutics | BRAF | Small molecule | Ph2 | NCT05503797 |
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Temozolomide | GT Medical Technologies, Inc. | |
| Bevacizumab | Medical University of Vienna | |
| Cyclophosphamide | Children's Oncology Group | |
| Lomustine | CarThera | |
| Vorasidenib | Megan Mantica | |
| Safusidenib | Nuvation Bio Inc. | |
| Ipilimumab | National Cancer Institute (NCI) | |
| Selumetinib Sulfate | National Cancer Institute (NCI) | |
| Dabrafenib | University of California, San Francisco | |
| Tovorafenib | Nationwide Children's Hospital | |
| Everolimus | Gustave Roussy, Cancer Campus, Grand Paris | |
| HMPL-306 tablet | Hutchmed | |
| 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution | Lee's Pharmaceutical Limited | |
| Induction Cycles A1-A3 | Nationwide Children's Hospital | |
| Tris-CAR-T cell injection | Beijing Tiantan Hospital | |
| Satralizumab | Hoffmann-La Roche | |
| DexamethasoneGroup III (n=25) | Tanta University | |
| Metformin hydrochloride (HCl) | Donald Mabbott | |
| Metformin | The Hospital for Sick Children | |
| Cerebraca wafer | Everfront Biotech Co., Ltd. | |
| Carboplatin and Vincristine | Alicia Lenzen | |
| TLX-101-Tx + Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | |
| Niraparib | Ivy Brain Tumor Center | |
| Tofacitinib | University of Texas Southwestern Medical Center | |
| Extended Release Flucytosine | NRG Oncology | |
| Dordaviprone | Jazz Pharmaceuticals | |
| Ferumoxytol | Jonsson Comprehensive Cancer Center | |
| 5 Aminolevulinic Acid | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | |
| CETEG | University Hospital Heidelberg | |
| Elucirem | Guerbet |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07912398 HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations No sites listed Decision brief → | Ph3 | Hutchmed | not yet recruiting | 2026-11-03 | 2032-03 |
| CAR-T · NCT07873996 Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Beijing Tiantan Hospital | not yet recruiting | 2026-10-14 | 2030-10-15 |
| NCT07869524 IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma Single-country: China (1 site) Decision brief → | Ph3 | Shandong Cancer Hospital and Institute | not yet recruiting | 2026-10-09 | 2030-12-31 |
| NCT07712757 Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma No sites listed Decision brief → | Ph3 | Nuvation Bio Inc. | not yet recruiting | 2026-07-17 | 2029-05 |
| NCT07698457 Clinical Benefit of 18F-FET in Glioma. Single-country: Taiwan (4 sites) Decision brief → | Ph3 | Primo Biotechnology Co., Ltd | not yet recruiting | 2026-07-13 | 2027-11-30 |
| NCT07461948 Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients Single-country: United States (1 site) Decision brief → | Ph3 | Jonsson Comprehensive Cancer Center | recruiting | 2026-03-10 | 2028-10-27 |
| NCT07452458 Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Single-country: United States (54 sites) Decision brief → | Ph3 | NRG Oncology | recruiting | 2026-03-05 | 2030-01-15 |
| DETERMINE · NCT07440290 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Single-country: United Kingdom (27 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2026-02-27 | 2029-10 |
| BrainUS-AI · NCT07376304 Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI No sites listed Decision brief → | Ph3 | Hospital del Rio Hortega | not yet recruiting | 2026-01-29 | 2027-12 |
| Cerebraca-02/3 · NCT07349693 Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | Everfront Biotech Co., Ltd. | not yet recruiting | 2026-01-20 | 2029-03-30 |
| NCT07291102 Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma Single-country: United States (2 sites) Decision brief → | Ph3 | Nationwide Children's Hospital | not yet recruiting | 2025-12-18 | 2034-10 |
| NCT07215910 Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Single-country: United States (177 sites) Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | recruiting | 2025-10-14 | 2033-05-31 |
| BRIDGES · NCT07195591 Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care Single-country: United States (22 sites) Decision brief → | Ph3 | GT Medical Technologies, Inc. | recruiting | 2025-09-26 | 2031-12 |
| IPAX BrIGHT · NCT07100730 Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma 4 countries, 0% of sites in the US Decision brief → | Ph3 | Telix Pharmaceuticals (Innovations) Pty Limited | recruiting | 2025-08-03 | 2027-07 |
| BRAINS · NCT06888817 Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases Single-country: Netherlands (6 sites) Decision brief → | Ph3 | The Netherlands Cancer Institute | recruiting | 2025-03-21 | 2028-07 |
| VIGOR · NCT06809322 Vorasidenib Maintenance for IDH Mutant Astrocytoma 12 countries, 0% of sites in the US Decision brief → | Ph3 | European Organisation for Research and Treatment of Cancer - EORTC | recruiting | 2025-02-05 | 2035-04-13 |
| NCT06780930 Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation 2 countries, 0% of sites in the US Decision brief → | Ph3 | Servier | active not recruiting | 2025-01-17 | 2026-05-07 |
| NCT06750458 Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients Single-country: Egypt (1 site) Decision brief → | Ph3 | Tanta University | completed | 2024-12-27 | 2026-09-20 |
| EF-41 · NCT06556563 EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma 12 countries, 35% of sites in the US Decision brief → | Ph3 | NovoCure GmbH | active not recruiting | 2024-08-16 | 2029-04 |
| NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Single-country: Taiwan (2 sites) Decision brief → | Ph3 | NaviFUS Corporation | recruiting | 2024-07-11 | 2026-12-31 |
| NCT06448286 PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Single-country: United States (1 site) Decision brief → | Ph3 | Jonsson Comprehensive Cancer Center | not yet recruiting | 2024-06-07 | 2030-12-01 |
| NCT06419946 Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma 4 countries, 0% of sites in the US Decision brief → | Ph3 | Vastra Gotaland Region | recruiting | 2024-05-17 | 2031-12-15 |
| NCT06417281 Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） Single-country: China (1 site) Decision brief → | Ph3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | completed | 2024-05-16 | 2025-08-19 |
| NCT06388733 A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma 11 countries, 34% of sites in the US Decision brief → | Ph3 | Ivy Brain Tumor Center | active not recruiting | 2024-04-29 | 2027-12 |
| NCT06160492 5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma Single-country: China (2 sites) Decision brief → | Ph3 | Lee's Pharmaceutical Limited | recruiting | 2023-12-07 | 2027-12 |
| NCT06105619 A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Beijing Pearl Biotechnology Limited Liability Company | active not recruiting | 2023-10-27 | 2023-04-01 |
| GDX-44-016 · NCT06057168 Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas 3 countries, 0% of sites in the US Decision brief → | Ph3 | Guerbet | completed | 2023-09-28 | 2024-11-28 |
| LEGATO · NCT05904119 Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study 11 countries, 0% of sites in the US Decision brief → | Ph3 | European Organisation for Research and Treatment of Cancer - EORTC | recruiting | 2023-06-15 | 2027-09 |
| SONOBIRD · NCT05902169 Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM 11 countries, 41% of sites in the US Decision brief → | Ph3 | CarThera | active not recruiting | 2023-06-13 | 2028-01-28 |
| ACTION · NCT05580562 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) 18 countries, 41% of sites in the US Decision brief → | Ph3 | Jazz Pharmaceuticals | recruiting | 2022-10-14 | 2028-06 |
| NCT05566795 DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) 30 countries, 28% of sites in the US Decision brief → | Ph3 | Day One Biopharmaceuticals, Inc. | active not recruiting | 2022-10-04 | 2027-06 |
| Cielo · NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis 15 countries, 20% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2022-08-16 | 2026-12-16 |
| BIOMEDE 2 · NCT05476939 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 8 countries, 0% of sites in the US Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | recruiting | 2022-07-27 | 2028-09 |
| NCT05382338 A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss 2 countries, 95% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2022-05-19 | 2029-12-31 |
| ImproveCodel · NCT05331521 A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). Single-country: Germany (19 sites) Decision brief → | Ph3 | University Hospital Heidelberg | recruiting | 2022-04-15 | 2033-03-31 |
| NCT05326464 Tofacitinib in Recurrent GBM Patients Single-country: United States (1 site) Decision brief → | Ph3 | University of Texas Southwestern Medical Center | completed | 2022-04-13 | 2025-02-18 |
| SIGMA · NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) 3 countries, 75% of sites in the US Decision brief → | Ph3 | Nuvation Bio Inc. | recruiting | 2022-03-31 | 2028-12-01 |
| NCT05271240 Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Single-country: United States (1 site) Decision brief → | Ph3 | Northwell Health | recruiting | 2022-03-08 | 2027-04-01 |
| Met Med Can · NCT05230758 Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour 2 countries, 0% of sites in the US Decision brief → | Ph3 | Donald Mabbott | recruiting | 2022-02-09 | 2027-11-30 |
| NCT05095376 Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma 2 countries, 100% of sites in the US Decision brief → | Ph3 | NRG Oncology | active not recruiting | 2021-10-27 | 2026-02-12 |
| POLO · NCT04702581 A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery Single-country: France (26 sites) Decision brief → | Ph3 | Hospices Civils de Lyon | recruiting | 2021-01-11 | 2030-12 |
| NCT04576117 A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma 2 countries, 90% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2020-10-06 | 2026-12-30 |
| NCT04396860 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Single-country: United States (285 sites) Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | completed | 2020-05-21 | 2023-01-13 |
| NCT04166409 A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma 3 countries, 94% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2019-11-18 | 2030-12-31 |
| NCT04105374 Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2/Ph3 | NRG Oncology | withdrawn | 2019-09-26 | 2025-11-30 |
| GBM AGILE · NCT03970447 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma 6 countries, 67% of sites in the US Decision brief → | Ph2/Ph3 | Global Coalition for Adaptive Research | recruiting | 2019-05-31 | 2028-06 |
| NCT03871257 A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma 3 countries, 95% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2019-03-12 | 2027-12-31 |
| StrateGlio · NCT03663725 Treatment Intensification With Temozolomide in Adults With a Glioblastoma Single-country: France (17 sites) Decision brief → | Ph3 | Centre Oscar Lambret | active not recruiting | 2018-09-10 | 2027-06 |
| RE-GEND · NCT02761070 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Single-country: Japan (37 sites) Decision brief → | Ph3 | Kyorin University | completed | 2016-05-04 | 2025-04-17 |
| NCT02455245 A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Single-country: United States (21 sites) Decision brief → | Ph3 | Alicia Lenzen | completed | 2015-05-27 | 2025-08-31 |
| POLCA · NCT02444000 gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas Single-country: France (33 sites) Decision brief → | Ph3 | Assistance Publique - Hôpitaux de Paris | completed | 2015-05-14 | 2022-10-11 |
| NCT02152982 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme 2 countries, 100% of sites in the US Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-06-02 | 2021-12-01 |
| NCT02040376 Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma Single-country: Canada (1 site) Decision brief → | Ph3 | The Hospital for Sick Children | completed | 2014-01-20 | 2017-12-15 |
| SPECTRO GLIO · NCT01507506 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Single-country: France (12 sites) Decision brief → | Ph3 | Institut Claudius Regaud | terminated | 2012-01-11 | 2020-01-02 |
| NCT01096368 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma 4 countries, 87% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2010-03-31 | 2021-12-31 |
| NCT00978458 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Single-country: United States (168 sites) Decision brief → | Ph3 | Eastern Cooperative Oncology Group | active not recruiting | 2009-09-17 | 2026-12-31 |
| NCT00887146 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma 6 countries, 93% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | active not recruiting | 2009-04-23 | 2029-10-31 |
| NCT00392327 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET 5 countries, 92% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2006-10-26 | 2019-06-30 |
| NCT00336024 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma 4 countries, 89% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2006-06-12 | 2016-12-31 |
| NCT00085735 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma 7 countries, 88% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2004-06-16 | 2016-03-31 |
| NCT07916389 Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | not yet recruiting | 2026-11-04 | 2034-11 |
| ALERT-1 · NCT07902037 A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) No sites listed Decision brief → | Ph1/Ph2 | Siren Biotechnology | not yet recruiting | 2026-10-28 | 2030-01 |
| NCT07891286 Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Single-country: United States (1 site) Decision brief → | Ph2 | National Cancer Institute (NCI) | not yet recruiting | 2026-10-23 | 2029-01-04 |
| STAR-VACC · NCT07888647 IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas Single-country: Germany (13 sites) Decision brief → | Ph2 | German Cancer Research Center | not yet recruiting | 2026-10-22 | 2034-02-01 |
| NCT07859059 Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Nebraska | not yet recruiting | 2026-10-05 | 2030-06-01 |
| NCT07856069 Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | not yet recruiting | 2026-10-02 | 2030-10 |
| NCT07831187 Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence Single-country: China (1 site) Decision brief → | Ph1/Ph2 | First Affiliated Hospital of Wenzhou Medical University | not yet recruiting | 2026-09-21 | 2029-09-30 |
| SAFU-G3 · NCT07832123 Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Single-country: Switzerland (1 site) Decision brief → | Ph2 | University of Zurich | not yet recruiting | 2026-09-21 | 2029-03 |
| NCT07831369 VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma Single-country: United States (1 site) Decision brief → | Ph2 | Inova Health Care Services | recruiting | 2026-09-21 | 2027-09-30 |
| ENDURANCE · NCT07821112 Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® Single-country: United States (1 site) Decision brief → | Ph2 | University of California, Irvine | not yet recruiting | 2026-09-15 | 2027-10 |
| NCT07811297 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Advenchen Pharmaceuticals, LLC. | not yet recruiting | 2026-09-10 | 2030-09-01 |
| NCT07789379 Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma No sites listed Decision brief → | Ph2 | Wei Jiang | not yet recruiting | 2026-08-27 | 2028-10-01 |
| TIGER-1 · NCT07767110 Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response No sites listed Decision brief → | Ph1/Ph2 | NanOlogy, LLC | not yet recruiting | 2026-08-17 | 2029-12 |
| NCT07762716 Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | BreakBio Corp | not yet recruiting | 2026-08-13 | 2030-09 |
| ELITE · NCT07758062 Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma Single-country: China (1 site) Decision brief → | Ph2 | Tianjin Medical University General Hospital | not yet recruiting | 2026-08-11 | 2029-08-01 |
| NCT07754734 STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation No sites listed Decision brief → | Ph2 | Dongguan People's Hospital | not yet recruiting | 2026-08-10 | 2029-07-31 |
| NCT07751744 Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma No sites listed Decision brief → | Ph1/Ph2 | Jubilant Therapeutics Inc. | not yet recruiting | 2026-08-07 | 2030-03-31 |
| NCT07735819 Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma Single-country: United States (1 site) Decision brief → | Ph2 | Barbara Ann Karmanos Cancer Institute | not yet recruiting | 2026-07-30 | 2031-06-30 |
| NCT07715097 Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2 | Beijing Tricision Biotherapeutics Inc | not yet recruiting | 2026-07-20 | 2028-09-30 |
| PRIME-NF2 · NCT07713745 Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Single-country: China (5 sites) Decision brief → | Ph2 | Beijing Tiantan Hospital | not yet recruiting | 2026-07-20 | 2036-06-01 |
| ASSIST · NCT07707947 Selumetinib for NF2-Related Schwannomatosis Single-country: China (1 site) Decision brief → | Ph2 | Beijing Tiantan Hospital | not yet recruiting | 2026-07-16 | 2028-12-31 |
| NCT07708961 Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma Single-country: United States (3 sites) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2026-07-16 | 2036-08-31 |
| Nimotuzumab · NCT07707973 Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma No sites listed Decision brief → | Ph2 | Tianjin First Central Hospital | not yet recruiting | 2026-07-16 | 2028-01-03 |
| NCT07703436 Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Single-country: United States (12 sites) Decision brief → | Ph2 | Nuvation Bio Inc. | recruiting | 2026-07-14 | 2030-09 |
| NCT07694089 Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas Single-country: United States (2 sites) Decision brief → | Ph2 | Akshitkumar MIstry | not yet recruiting | 2026-07-09 | 2029-08-01 |
| NCT07680439 Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). Single-country: United States (6 sites) Decision brief → | Ph2 | BrainChild Bio, Inc | recruiting | 2026-07-02 | 2028-10 |
| NCT07678684 A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma Single-country: China (1 site) Decision brief → | Ph2 | HighField Biopharmaceuticals Corporation | recruiting | 2026-07-01 | 2028-12-31 |
| NCT07670026 Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression Single-country: China (1 site) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2026-06-25 | 2027-12-01 |
| NCT07649070 Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2026-06-15 | 2030-12-31 |
| NCT07644312 Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG No sites listed Decision brief → | Ph2 | Nationwide Children's Hospital | not yet recruiting | 2026-06-12 | 2033-03-01 |
| NCT07620548 Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas Single-country: United States (2 sites) Decision brief → | Ph2 | Washington University School of Medicine | not yet recruiting | 2026-06-02 | 2031-05-31 |
| NCT07609472 FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma Single-country: United States (5 sites) Decision brief → | Ph2 | FluoGuide A/S | not yet recruiting | 2026-05-27 | 2028-07-31 |
| NOVA-GBM · NCT07604285 A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Myosin Therapeutics Inc. | not yet recruiting | 2026-05-22 | 2027-03 |
| NCT07599371 A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | The First Affiliated Hospital of Zhengzhou University | recruiting | 2026-05-20 | 2027-10-10 |
| NCT07589257 A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma Single-country: China (1 site) Decision brief → | Ph2 | Guangzhou Virotech Pharmaceutical Co., Ltd. | recruiting | 2026-05-15 | 2028-06-30 |
| NCT07567469 A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma No sites listed Decision brief → | Ph1/Ph2 | Regeneron Pharmaceuticals | not yet recruiting | 2026-05-05 | 2032-08-27 |
| FIDES · NCT07562971 Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES) Single-country: Netherlands (2 sites) Decision brief → | Ph1/Ph2 | UMC Utrecht | not yet recruiting | 2026-05-01 | 2030-11 |
| NCT07542158 Ultralow Dose PET Imaging of 18F-FDOPA Single-country: United States (1 site) Decision brief → | Ph2 | Akiva Mintz | enrolling by invitation | 2026-04-21 | 2030-06-30 |
| NCT07539441 A Study of Mirdametinib in People With Central Nervous System Tumors Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-04-20 | 2029-10-10 |
| NF118 · NCT07521657 Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma Single-country: United States (1 site) Decision brief → | Ph2 | University of Alabama at Birmingham | not yet recruiting | 2026-04-13 | 2031-01-01 |
| SELECT-2CAR · NCT07523529 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Biotech | recruiting | 2026-04-13 | 2027-04-14 |
| PRISM · NCT07511725 Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma Single-country: China (1 site) Decision brief → | Ph2 | Second Affiliated Hospital, Zhejiang University, School of Medicine | recruiting | 2026-04-06 | 2028-01-04 |
| NCT07501156 H3K27M-specific Immune Effector Cells Targeting DMG/DIPG Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2026-03-30 | 2029-12-31 |
| NCT07501559 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Jecho Biopharmaceuticals Co., Ltd. | recruiting | 2026-03-30 | 2030-04 |
| TEMPO · NCT07476794 Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma Single-country: Canada (1 site) Decision brief → | Ph2 | Sunnybrook Health Sciences Centre | recruiting | 2026-03-17 | 2027-10 |
| NCT07468136 Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Mayo Clinic | recruiting | 2026-03-12 | 2030-10-25 |
| NCT07462507 Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 Single-country: United States (1 site) Decision brief → | Ph2 | Washington University School of Medicine | recruiting | 2026-03-10 | 2031-06-30 |
| PRC · NCT07439172 Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. Single-country: United States (1 site) Decision brief → | Ph2 | Cooper Norcross Health | recruiting | 2026-02-27 | 2028-09 |
| NCT07431216 A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression No sites listed Decision brief → | Ph1/Ph2 | Starlight Therapeutics Inc. | not yet recruiting | 2026-02-24 | 2027-05-01 |
| PED-DNX2401 · NCT07424092 Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors 2 countries, 0% of sites in the US Decision brief → | Ph2 | Clinica Universidad de Navarra, Universidad de Navarra | recruiting | 2026-02-20 | 2029-05 |
| NCT07416188 Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Institute of Neurological Disorders and Stroke (NINDS) | recruiting | 2026-02-18 | 2030-12-31 |
| TUVASTRAT · NCT07417761 Tuvusertib in Astrocytoma With ATRX Mutation Single-country: Spain (10 sites) Decision brief → | Ph2 | Grupo Español de Investigación en Neurooncología | recruiting | 2026-02-18 | 2028-09 |
| SELECT-CAR-NK · NCT07410494 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2026-02-13 | 2027-12-28 |
| EBNK-ST-001 · NCT07410676 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2026-02-13 | 2028-12-21 |
| NCT07392957 Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Washington University School of Medicine | recruiting | 2026-02-06 | 2029-06-30 |
| NCT07389278 Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Sabine Mueller, MD, PhD | not yet recruiting | 2026-02-05 | 2032-06-30 |
| 5G-PEARL · NCT07391215 5G-PEARL: Paxalisib in Malignant Brain Tumours Single-country: United Kingdom (1 site) Decision brief → | Ph1/Ph2 | Institute of Cancer Research, United Kingdom | recruiting | 2026-02-05 | 2029-01-19 |
| GLIOMAX-101 · NCT07386002 The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma 2 countries, 25% of sites in the US Decision brief → | Ph2 | T-MAXIMUM Pharmaceutical Inc | not yet recruiting | 2026-02-04 | 2028-12-13 |
| NCT07365280 Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma No sites listed Decision brief → | Ph2 | ZSky Biotech Inc | not yet recruiting | 2026-01-26 | 2028-12-24 |
| AFGBMBiop · NCT07364786 Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma Single-country: Sweden (1 site) Decision brief → | Ph2 | Peter Siesjö | recruiting | 2026-01-23 | 2026-10 |
| OPTICAL · NCT07356973 Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma Single-country: United Kingdom (1 site) Decision brief → | Ph2 | CRISM Therapeutics LTD | recruiting | 2026-01-21 | 2029-05 |
| ADePT · NCT07346144 Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma 2 countries, 50% of sites in the US Decision brief → | Ph1/Ph2 | Trogenix ltd | recruiting | 2026-01-16 | 2030-03 |
| PNOC044 · NCT07346157 Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Sabine Mueller, MD, PhD | recruiting | 2026-01-16 | 2031-03-31 |
| NCT07326566 Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Single-country: United States (38 sites) Decision brief → | Ph2 | Black Diamond Therapeutics, Inc. | recruiting | 2026-01-08 | 2028-11 |
| NCT07301268 GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Single-country: United States (1 site) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-12-24 | 2029-09-01 |
| NCT07297212 A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma Single-country: China (6 sites) Decision brief → | Ph2 | BioNTech SE | recruiting | 2025-12-22 | 2028-01 |
| NCT07285044 The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Single-country: United States (1 site) Decision brief → | Ph2 | Mayo Clinic | recruiting | 2025-12-16 | 2027-05-15 |
| ReVoGlio · NCT07284628 Vortioxetine for Newly Diagnosed Glioblastoma Single-country: Switzerland (1 site) Decision brief → | Ph2 | University of Zurich | recruiting | 2025-12-16 | 2029-06 |
| Phenix · NCT07263438 Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial Single-country: Switzerland (7 sites) Decision brief → | Ph2 | Centre Hospitalier Universitaire Vaudois | recruiting | 2025-12-04 | 2028-03-30 |
| TARLATEM · NCT07243470 Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors Single-country: France (12 sites) Decision brief → | Ph1/Ph2 | Centre Leon Berard | recruiting | 2025-11-24 | 2029-10 |
| NCT07243340 A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor Single-country: China (1 site) Decision brief → | Ph1/Ph2 | ImmVira Pharma Co. Ltd | recruiting | 2025-11-21 | 2027-12-15 |
| NCT07225621 Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma Single-country: United States (11 sites) Decision brief → | Ph2 | Alpheus Medical, Inc. | recruiting | 2025-11-06 | 2027-12 |
| NCT07206849 Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) No sites listed Decision brief → | Ph2 | Nationwide Children's Hospital | not yet recruiting | 2025-10-03 | 2030-02 |
| STAR-GBM · NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Myosin Therapeutics Inc. | recruiting | 2025-09-22 | 2026-10-31 |
| NCT07180927 DLL3 CAR-T Therapy Targeting Brain Tumors Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2025-09-18 | 2028-05-31 |
| NCT07126990 Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Xiaorong Wu | enrolling by invitation | 2025-08-17 | 2028-08-30 |
| PNOC037 · NCT07110246 Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Single-country: United States (12 sites) Decision brief → | Ph2 | University of California, San Francisco | recruiting | 2025-08-07 | 2032-03-31 |
| NCT07093814 A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma Single-country: China (11 sites) Decision brief → | Ph1/Ph2 | Guangzhou Virotech Pharmaceutical Co., Ltd. | recruiting | 2025-07-30 | 2028-12-31 |
| NCT07003542 A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Single-country: United States (1 site) Decision brief → | Ph2 | Case Comprehensive Cancer Center | recruiting | 2025-06-04 | 2027-06 |
| NCT06991101 Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma Single-country: United States (2 sites) Decision brief → | Ph2 | Baptist Health South Florida | recruiting | 2025-05-25 | 2030-12 |
| ADVICE · NCT06926075 Early Phase Study of KESONOTIDE™in Participants With Solid Tumours Single-country: Australia (3 sites) Decision brief → | Ph1/Ph2 | Filamon LTD | recruiting | 2025-04-13 | 2027-10-26 |
| NCT06914128 A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors 13 countries, 27% of sites in the US Decision brief → | Ph1/Ph2 | Bayer | recruiting | 2025-04-06 | 2029-06-18 |
| NCT06894225 Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature Single-country: Singapore (1 site) Decision brief → | Ph2 | National Neuroscience Institute | recruiting | 2025-03-25 | 2027-05 |
| NCT06855628 Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) Single-country: United States (1 site) Decision brief → | Ph2 | Stanford University | completed | 2025-03-04 | 2026-07-13 |
| NCT06838676 ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas 5 countries, 60% of sites in the US Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2025-02-21 | 2028-07 |
| RABBIT · NCT06814496 Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | University of Arizona | recruiting | 2025-02-07 | 2030-05 |
| NCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss Single-country: United States (15 sites) Decision brief → | Ph1/Ph2 | Tango Therapeutics, Inc. | recruiting | 2025-02-05 | 2027-03-31 |
| EViDENCE-BT · NCT06804655 Pharmacoscopy for Patients With Refractory Primary Brain Tumors Single-country: Switzerland (3 sites) Decision brief → | Ph2 | University of Zurich | recruiting | 2025-02-03 | 2028-09-15 |
| NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) Single-country: United States (18 sites) Decision brief → | Ph2 | Diakonos Oncology Corporation | recruiting | 2025-02-03 | 2030-03 |
| NCT06763965 Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | enrolling by invitation | 2025-01-08 | 2027-07-31 |